奥浦迈: 奥浦迈：关于发行股份及支付现金购买资产并募集配套资金的审核问询函回复的提示性公告

Core Viewpoint - The company plans to acquire 100% equity of Pengli Biopharmaceutical Technology (Shanghai) Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds from no more than 35 specific investors [1][2]. Group 1 - The company has received an inquiry letter from the Shanghai Stock Exchange regarding the proposed transaction, which includes the issuance of shares and cash payment for asset acquisition [1][2]. - The company and related intermediaries have responded to the inquiry letter by providing detailed explanations and revisions to the transaction draft [2]. - The transaction is subject to multiple conditions, including approval from the Shanghai Stock Exchange and registration consent from the China Securities Regulatory Commission, which introduces uncertainty regarding the final approval and registration timeline [2].